Epigenetic Reprogramming of CD4+ Helper T Cells as a Strategy to Improve Anticancer Immunotherapy

Elodie Renaude; Elodie Renaude; Marie Kroemer; Marie Kroemer; Christophe Borg; Christophe Borg; Christophe Borg; Paul Peixoto; Paul Peixoto; Eric Hervouet; Eric Hervouet; Eric Hervouet; Romain Loyon; Olivier Adotévi; Olivier Adotévi; Olivier Adotévi

doi:10.3389/fimmu.2021.669992

Frontiers in Immunology (Jun 2021)

Epigenetic Reprogramming of CD4+ Helper T Cells as a Strategy to Improve Anticancer Immunotherapy

Elodie Renaude,
Elodie Renaude,
Marie Kroemer,
Marie Kroemer,
Christophe Borg,
Christophe Borg,
Christophe Borg,
Paul Peixoto,
Paul Peixoto,
Eric Hervouet,
Eric Hervouet,
Eric Hervouet,
Romain Loyon,
Olivier Adotévi,
Olivier Adotévi,
Olivier Adotévi

Affiliations

Elodie Renaude: University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France
Elodie Renaude: Centre Hospitalier Universitaire de Besançon, Centre d’Investigation Clinique, INSERM CIC 1431, Besançon, France
Marie Kroemer: University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France
Marie Kroemer: Department of Pharmacy, University Hospital of Besançon, Besançon, France
Christophe Borg: University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France
Christophe Borg: Centre Hospitalier Universitaire de Besançon, Centre d’Investigation Clinique, INSERM CIC 1431, Besançon, France
Christophe Borg: Department of Medical Oncology, University Hospital of Besançon, Besançon, France
Paul Peixoto: University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France
Paul Peixoto: EPIGENEXP Platform, University of Bourgogne Franche-Comté, Besançon, France
Eric Hervouet: University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France
Eric Hervouet: EPIGENEXP Platform, University of Bourgogne Franche-Comté, Besançon, France
Eric Hervouet: DImaCell Platform, University of Bourgogne Franche-Comté, Besançon, France
Romain Loyon: University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France
Olivier Adotévi: University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France
Olivier Adotévi: Centre Hospitalier Universitaire de Besançon, Centre d’Investigation Clinique, INSERM CIC 1431, Besançon, France
Olivier Adotévi: Department of Medical Oncology, University Hospital of Besançon, Besançon, France

DOI: https://doi.org/10.3389/fimmu.2021.669992
Journal volume & issue: Vol. 12

Abstract

Read online

Evidences highlight the role of various CD4+ helper T cells (CD4+ Th) subpopulations in orchestrating the immune responses against cancers. Epigenetics takes an important part in the regulation of CD4+ Th polarization and plasticity. In this review, we described the epigenetic factors that govern CD4+ T cells differentiation and recruitment in the tumor microenvironment and their subsequent involvement in the antitumor immunity. Finally, we discussed how to manipulate tumor reactive CD4+ Th responses by epigenetic drugs to improve anticancer immunotherapy.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords